Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: Extended follow-up and rate of relapse

American Journal of Medicine

Volumn 114, Issue 6, 2003, Pages 463-469

  Langford, Carol A ^a,b   Talar Williams, Cheryl ^a   Barron, Karyl S ^a   Sneller, Michael C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cyclophosphamide; Methotrexate; Relapse; Treatment; Wegener's

Indexed keywords

CALCITRIOL; CALCIUM CARBONATE; CYCLOPHOSPHAMIDE; ETIDRONIC ACID; FOLINATE CALCIUM; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ADOLESCENT; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AVASCULAR NECROSIS; BACTERIAL PNEUMONIA; CATARACT; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DEATH; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART INFARCTION; HERPES ZOSTER; HUMAN; LABORATORY TEST; LEUKOPENIA; MALE; OSTEOPOROSIS; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIODIAGNOSIS; RECURRENCE RISK; REMISSION; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT OUTCOME; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0037447483     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(03)00077-9     Document Type: Article

References (15)

1. Fauci A., Haynes B., Katz P., Wolff S. Wegener's granulomatosis prospective clinical and therapeutic experience with 85 patients for 21 years . Ann Intern Med. 98:1983;76-85.
2. Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener granulomatosis an analysis of 158 patients . Ann Intern Med. 116:1992;488-494.
3. Langford C.A., Talar-Williams C., Barron K.S., Sneller M.C. A staged approach to the treatment of Wegener's granulomatosis induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance . Arthritis Rheum. 42:1999;2666-2673.
4. Leavitt R.Y., Fauci A.S., Bloch D.A., et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 33:1990;1101-1107.
5. Sneller M.C., Hoffman G.S., Talar-Williams C., et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum. 38:1995;608-613.
6. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 39:1996;1791-1801.
7. Adachi J.D., Bensen W.G., Brown J., et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 337:1997;382-387.
8. Kerr G.S., Fleisher T.A., Hallahan C.W., et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum. 36:1993;365-371.
9. Kaplan E., Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
10. Reinhold-Keller E., Beuge N., Latza U., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis long-term outcome in 155 patients . Arthritis Rheum. 43:2000;1021-1032.
11. Guillevin L., Cordier J.F., Lhote F., et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 40:1997;2187-2198.
12. Talar-Williams C., Hijazi Y.M., Walther M.M., et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 124:1996;477-484.
13. Cotch M.F., Hoffman G.S., Yerg D.E., et al. The epidemiology of We-gener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum. 39:1996;87-92.
14. Reinhold-Keller E., Fink C.O.E., Herlyn K., et al. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Care Res. 47:2002;326-332.
15. Jayne D. Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol. 13:2001;48-55.